Research advances in the role of blood metabolic markers in the treatment response and prognosis prediction of primary liver cancer
10.3969/j.issn.1001-5256.2023.10.028
- VernacularTitle:血液代谢标志物在原发性肝癌治疗反应及预后预测中的应用
- Author:
Zhiying LIU
1
;
Zhihang ZHOU
1
;
Song HE
1
Author Information
1. Department of Gastroenterology， The Second Affiliated Hospital of Chongqing Medical University， Chongqing 400010， China
- Publication Type:Review
- Keywords:
Liver Neoplasms;
Biomarkers;
Therapeutics;
Prognosis
- From:
Journal of Clinical Hepatology
2023;39(10):2470-2475
- CountryChina
- Language:Chinese
-
Abstract:
Primary liver cancer is one of the most severe cancer burdens around the world. Metabolic reprogramming is one phenotype of cancer， and blood metabolic markers are closely associated with metabolic reprogramming and can predict the risk of recurrence and survival or assess the treatment response of liver cancer， with important significance in the stratified management of patients， the development of rational treatment strategies， and the improvement of patient prognosis. By reviewing the recent studies on blood metabolomics in assessing the treatment response or predicting the prognosis of liver cancer， this article summarizes the blood metabolites with predictive significance and their mechanism of action and analyzes the current research status， existing problems， and prospects of this field. It is believed that the metabolites， such as aromatic amino acids， lipids， and bile acids， have an important clinical value in predicting the prognosis of liver cancer， and metabolomics technology has great potential in finding useful metabolites， but there are still many issues to be solved， such as technical limitations， insufficient studies， and multiple influencing factors.
